-The Times of India Railway minister Dinesh Trivedi on Wednesday did what none of his predecessors had done for almost a decade - he hiked passenger fares across the board, following up on the increase in freight charges announced immediately after the recent round of assembly elections. While biting the bullet in hiking fares, he chose to couch the increase as ranging from a mere two paise per km for second class...
More »SEARCH RESULT
Total Matching Records found : 5845
Why this will be a reform budget-Surjit S Bhalla
Most of us don’t even get a single shot at making history — Manmohan Singh has a second chance The fiscal deficit is an outcome, not a policy. It is the net resolution of the policies pertaining to taxes and expenditure. It is worth analysing separately the two components of the deficit. The table reports the results of relating the tax and expenditure share of GDP to per capita income for...
More »Agri report calls for growth on a par with GDP by Sandip Das
A report on ‘State of Indian Agriculture 2011-12’, tabled in the Lok Sabha on Tuesday, has called for reforms to ensure that the sector grows in tandem with the overall GDP of the country. The report says that “achieving an 8-9% rate of growth in the overall GDP may not deliver much in terms of poverty reduction unless agricultural growth accelerates”. Admitting that the sector has undergone ‘significant structural changes’ in...
More »Natco gets India’s first compulsory licence-CH Unnikrishnan
In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...
More »Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a FRAction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »
